United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.See the Zacks Earnings Calendar to stay ahead of market-making news.United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high-risk neuroblastoma.Revenues came in at $735.9 million, beating the Zacks Consensus Estimate of $725.3 million. Revenues rose 20% year over year, driven by meaningful growth of key products — Tyvaso, Remodulin, Orenitram and Unituxin.More on UTHR’s EarningsThe company markets two versions of Tyvaso — Tyvaso dry powder inhalation (DPI) and nebulized Tyvaso. Both versions are approved for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications.Tyvaso DPI recorded sales of $273.2 million, up 28% year over year, while sales from nebulized Tyvaso were $142.7 million, up 4%.Overall, Tyvaso sales were $415.9 million, up 19% year over year, driven by higher volumes and price increases, which were partially offset by higher gross-to-net deductions. Continued growth in commercialization utilization by PH-ILD patients led to patient growth, which in turn benefited volumes. Tyvaso sales, however, missed the Zacks Consensus Estimate of $425 million and our model estimate of $424.8 million.Remodulin (including Remunity Pump) sales rose 17% year over year to $134.5 million due to higher volume growth in the United States.Sales of Orenitram rose 28% year over year to $107.8 million, driven by higher volumes, partly due to increased commercialization following the implementation of the Part D redesign under the Inflation Reduction Act (IRA).Unituxin sales rose 25% year over year to $67.5 million. Adcirca sales were $4.7 million, down 31%.Shares of UTHR were down almost 4% in pre-market trading despite the earnings and sales beat. This could be because of lower-than-expected sales of Tyvaso.In the past year, shares of United Therapeutics have surged 57.6% against the industry’s 15.4% decline.Image Source: Zacks Investment ResearchResearch and development expenses were $133.8 million in the quarter, down 12% year over year due to certain in-process research and development (IPR&D) costs recorded in the year-ago quarter.Selling, general and administrative expenses surged 27% to $168.5 million in the quarter due to higher personnel expenses and legal costs.UTHR's Full-Year 2024 ResultsFull-quarter 2024 earnings of $24.64 per share beat the Zacks Consensus Estimate of $24.48. Earnings rose 124.3% year over year.Revenues were $2.89 billion, which beat the Zacks Consensus Estimate of $2.87 billion. Revenues rose 24% year over year.UTHR’s Pipeline & Other UpdateUnited Therapeutics’ key phase III programs include Tyvaso in patients with various forms of chronic fibrosing interstitial lung disease (TETON studies) and oral ralinepag in PAH indications (ADVANCE OUTCOMES study).The TETON 1 and TETON 2 studies are registrational late-stage studies evaluating a nebulized version of Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF). Enrollment is complete in both studies.Top-line data from the TETON-2 study is expected in second-half 2025. Data from the TETON 1 study is expected in the first half of 2026. If the drug is approved in the IPF indication, management expects Tyvaso sales to exceed the drug’s sales in the PAH indication.A phase III TETON PPF study is also ongoing to evaluate Tyvaso in patients with progressive pulmonary fibrosis.Data from ralinepag studies are expected next yearUnited Therapeutics has different kinds of organ manufacturing products in clinical and preclinical development. These include xenotransplantation, 3-D organ bioprinting, bio-artificial organs, regenerative medicine and ex-vivo lung perfusion.In February, the FDA cleared its investigational new drug application to start a clinical registration-enabling xenotransplantation study with its investigational UKidney derived from a 10 gene-edited source pig.UTHR’s Zacks Rank & Stocks to ConsiderUnited Therapeuticscurrently carries a Zacks Rank #4 (Sell).United Therapeutics Corporation Price and Consensus United Therapeutics Corporation price-consensus-chart | United Therapeutics Corporation QuoteSome better-ranked stocks from the sector are Immunocore IMCR, Pacira BioSciences PCRX and Amicus Therapeutics FOLD. While Immunocore and Pacira BioSciences currently sport a Zacks Rank #1 (Strong Buy) each, Amicus Therapeutics carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.In the past 30 days, estimates for Immunocore’s 2025 loss per share have narrowed from $1.66 to $1.62 per share. In the past year, shares of Immunocore have declined 58.5%.IMCR’s earnings beat estimates in two of the trailing four quarters, while missing in the remaining two, delivering an average surprise of 25.57%.In the past 30 days, estimates for Pacira BioSciences’ 2025 earnings per share have risen from $3.11 to $3.59. In the past year, shares of PCRX have declined 15.8%.Pacira BioSciences’ earnings beat estimates in two of the trailing four quarters, missed the same in one, while meeting estimates in the remaining quarter. The average four-quarter surprise is 7.13%.In the past 30 days, estimates for Amicus Therapeutics’ 2025 earnings per share have remained stable at 43 cents. In the past year, shares of FOLD have lost 34.2%.FOLD’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 45.42%.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Therapeutics Corporation (UTHR): Free Stock Analysis Report Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis Report Pacira BioSciences, Inc. (PCRX): Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks